Research Service, VA Portland Health Care System, Portland, Oregon, and Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon.
Research Service, VA Portland Health Care System, Portland, Oregon, and Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon
Mol Pharmacol. 2021 Aug;100(2):61-64. doi: 10.1124/molpharm.121.000284. Epub 2021 May 27.
We previously proposed that the dopamine D2 receptor-interacting protein S100B binds to a putative S100B-binding motif at residues R233-L240 toward the N terminus of the third intracellular loop. We used in vitro pull-down assays with FLAG-tagged fragments of the rat dopamine D2 receptor third intracellular loop (D2-IC3) and in vitro-synthesized S100B to evaluate this hypothesis. Our results indicate that the putative S100B-binding motif is neither necessary nor sufficient for strong binding of S100B to D2-IC3. Instead, two residues at the junction of the fifth membrane-spanning domain and the cytoplasmic extension of that -helical domain, K211-I212, are required for robust, calcium-sensitive binding of S100B. This is also the approximate location of previously identified determinants for the binding of arrestin and calmodulin. A D2 receptor mutation converting I212 to phenylalanine has been described in patients with a hyperkinetic movement disorder. SIGNIFICANCE STATEMENT: S100B is a small calcium-binding protein that modulates signaling by the dopamine D2 receptor. New data suggest that the previous hypothesis about the involvement of an S100B-binding motif is incorrect, and that an important determinant of S100B binding includes a residue that is mutated in patients with a hyperkinetic movement disorder.
我们之前提出,多巴胺 D2 受体相互作用蛋白 S100B 与第三细胞内环 N 端的假定 S100B 结合基序残基 R233-L240 结合。我们使用 FLAG 标记的大鼠多巴胺 D2 受体第三细胞内环(D2-IC3)片段和体外合成的 S100B 的体外下拉测定来评估这一假设。我们的结果表明,假定的 S100B 结合基序既不是 S100B 与 D2-IC3 强结合所必需的,也不是充分的。相反,第五跨膜域和该螺旋域胞质延伸交界处的两个残基 K211-I212 需要 S100B 的强、钙敏感性结合。这也是先前鉴定的与 arrestin 和钙调蛋白结合的决定因素的大致位置。已经在患有多动运动障碍的患者中描述了将 I212 转化为苯丙氨酸的 D2 受体突变。意义陈述:S100B 是一种调节多巴胺 D2 受体信号的小钙结合蛋白。新数据表明,关于涉及 S100B 结合基序的先前假设是不正确的,并且 S100B 结合的一个重要决定因素包括在患有多动运动障碍的患者中发生突变的残基。